Pharmafile Logo
Pharmafocus logo
Advanced Search

type 2 diabetes

Showing 15 posts of 46 posts found.

astrazeneca_building_white

AstraZeneca’s Phase 3 Farxiga data impresses in type 2 diabetes

June 11, 2019
Manufacturing and Production, Research and Development AstraZeneca, diabetes, farxiga, pharma, type 2 diabetes

AstraZeneca has presented new Phase 3 data at the American Diabetes Association (ADA) 79th Scientific Sessions in San Francisco on …

News

Sanofi’s Soliqua proves superior to GLP-1 RA therapies in reducing blood sugar levels

June 10, 2019
Research and Development, Sales and Marketing Sanofi, Soliqua, diabetes, pharma, type 2 diabetes

Sanofi has stepped up at the American Diabetes Association (ADA) 79th Scientific Sessions in San Francisco, revealing new data which …

News

Novo’s oral semaglutide tops Jardiance and Victoza in two type 2 diabetes trials

June 10, 2019
Research and Development, Sales and Marketing Novo Nordisk, diabetes, pharma, semaglutide, type 2 diabetes

Novo Nordisk has taken the opportunity at the American Diabetes Association (ADA) 79th Scientific Sessions to pull back the curtain …

News
novo_nordisk_flag

Novo Nordisk’s oral semaglutide outclasses Januvia with new data in type 2 diabetes

March 26, 2019
Manufacturing and Production, Research and Development Novo Nordisk, Ozempic, diabetes, pharma, type 2 diabetes

Novo Nordisk has revealed new dose-specific Phase 3a data for its glucagon-like peptide-1 (GLP-1) analogue oral semaglutide, indicating that the …

News
diabetes-777001_960_720

Lilly and Boehringer’s Trajenta matches glimepiride in delaying cardiovascular events in type 2 diabetes patients

February 15, 2019
Medical Communications, Research and Development Boehringer, Eli Lilly, cardiovascular disease, pharma, type 2 diabetes

Boehringer Ingelheim and Eli Lilly’s Trajenta (linagliptin) met its primary endpoint in a recent trial, it has emerged, proving itself …

News
lilly_building_with_american_flag_web

Lilly’s Trulicity reduces major cardiovascular events in “ambitious” trial of type 2 diabetes

November 7, 2018
Research and Development Eli Lilly, Trulicity, cardiovascular events, pharma, type 2 diabetes

Eli Lilly has revealed new data on Trulicity (dulaglutide), showing that glucagon-like peptide-1 (GLP-1) receptor agonist achieved its primary endpoint …

News
slimming-2728331_960_720

Effective preventative therapies for type 2 diabetes are underused, new research argues

October 30, 2018
Manufacturing and Production, Research and Development, Sales and Marketing diabetes, obesity, pharma, prediabetes, type 2 diabetes

New research has warned that interventions which can effectively delay or prevent the development of type 2 diabetes are not …

News
astrazeneca_building_white

AstraZeneca’s once-weekly auto-injector Bydureon BCise wins EU approval in type 2 diabetes

August 30, 2018
Research and Development, Sales and Marketing AstraZeneca, Bydureon, EU, Europe, diabetes, pharma, type 2 diabetes

AstraZeneca has announced that its auto-injector Bydureon BCise (exenatide 2mg prolonged-release suspension) has been approved by the European Commission for …

News
novo_nordisk_flag

Novo’s semaglutide hits the mark in Phase 3 type 2 diabetes study

August 21, 2018
Manufacturing and Production, Research and Development Novo Nordisk, diabetes, pharma, semaglutide, type 2 diabetes

Novo Nordisk has revealed new Phase 3a data on its glucagon-like peptide-1 (GLP-1) analogue oral semaglutide in the treatment of …

News
diabetes-777001_960_720

Researchers successfully minimise diabetes drug side-effects in animal models

July 17, 2018
Manufacturing and Production, Research and Development FDA, diabetes, pharma, type 2 diabetes

Researchers at the University of Pennsylvania and Syracuse University have modified a key ingredient of current diabetes drugs to produce …

News

Sanofi’s Toujeo proves non-inferior to insulin degludec in type 2 diabetes

June 26, 2018
Manufacturing and Production, Research and Development, Sales and Marketing American Diabetes Association, Sanofi, diabetes, insulin glargine, pharma, toujeo, type 2 diabetes

Sanofi took the opportunity at the American Diabetes Association (ADA) 78th Scientific Sessions in Florida to unveil new data on …

News
lilly_entrance_web

Eli Lilly partners with Chinese institution to advance the nation’s diabetes and CVD care

April 27, 2018
Medical Communications, Research and Development China, Eli Lilly, cardiovascular disorders, cvd, diabetes, pharma, type 2 diabetes

EIi Lilly has announced plans to partner up with China’s National Center for Cardiovascular Diseases (NCCD), the nation’s institution responsible …

News
diabetes-777001_960_720

Study reveals “concerning” low standards of type 2 diabetes drugs in India

March 7, 2018
Research and Development India, diabetes, pharma, regulatory, type 2 diabetes

In what they believe is the first study of its kind, a team of researchers at the University of Massachusetts …

News

Novo Nordisk delivers in much-anticipated oral semaglutide diabetes trial

February 23, 2018
Medical Communications, Research and Development Novo Nordisk, diabetes, pharma, semaglutide, type 2 diabetes

Novo Nordisk has lifted the curtain on much-anticipated results data from the first of ten Phase 3 trials into the …

News

Psoriasis patients at greater risk of type 2 diabetes, study reveals

November 15, 2017
Research and Development diabetes, pharma, psoriasis, type 2 diabetes

Researchers at the University of Pennsylvania’s Perelman School of Medicine have discovered that people with psoriasis are more at risk …

News

Latest content

AbbVie invests €150m in new R&D facility in Germany

May 3, 2024

AstraZeneca shares positive interim results from phase 3 lymphoma trial

May 3, 2024

Merck shares data from phase 3 trial of Keytruda for gastric cancers

May 2, 2024

Verona Pharma to share phase 3 COPD trial data at ATS 2024

May 2, 2024

Beckman Coulter Life Sciences and Watchmaker Genomics enter collaboration

May 1, 2024